Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Adisyn Ltd (ASX: AI1) has added a serious defence industry name to its newly formed Advisory Board, appointing former Israeli Air Defense Colonel Tamir Zimber as it seeks to turn its graphene-based radar absorption work into a commercial defence opportunity.

Zimber’s CV is not exactly short of acronyms or hardware. He was responsible for operational execution of Israel’s Iron Dome, Arrow, David’s Sling and Patriot systems, giving him direct experience with some of the world’s most closely watched air and missile defence platforms. He is currently Senior Director for Air Defense Systems in India at Israel Aerospace Industries, where Adisyn says he oversees multi-billion-dollar defence programs and manages engagement with government and military stakeholders.

For investors, the appointment matters because Adisyn is trying to move its radar signature reduction technology beyond the lab coat stage. The company has said graphene-enhanced composite materials have achieved up to 20dB radar signature reduction in laboratory testing, which it says could materially reduce the detectability of UAV and defence platforms. That is still early-stage work, but the strategic prize is obvious: drones are becoming cheaper, more numerous and more important, while the systems designed to detect them are becoming more sophisticated.

From clever material to usable product

Adisyn’s core technology pitch remains its graphene materials platform, including a patented low-temperature atomic layer deposition process targeting semiconductor applications. The defence angle is a second front, but it is fast becoming the more colourful one.

Last month, Adisyn secured exclusive worldwide commercialisation rights for graphene-based radar absorption technology under a binding Licence and Research Agreement with Ramot, the commercialisation arm of Tel Aviv University. That agreement included a 12-month research program focused on improving radar absorption performance, manufacturability and scalability, with the company previously flagging an expected program cost of less than $100,000.

The economic structure is also worth noting. 2D Radar Absorbers Ltd, the vehicle established for the radar absorption opportunity, is 81 per cent held by 2D Generation Ltd, a wholly owned Adisyn subsidiary, with Ramot holding 19 per cent. Ramot is also entitled to a 4 per cent royalty on net sales under the licence structure.

Zimber’s consideration is not cash, but options representing 1 per cent of 2D Radar Absorbers’ issued capital as at incorporation, exercisable at NIS 0.01 per share, subject to board approval. The options vest over 24 months, with a six-month cliff and monthly vesting thereafter. That aligns him with the success of the subsidiary rather than simply adding another consulting line item to the P&L.

The gap between proof and procurement

Managing director Arye Kohavi said Zimber’s appointment was “a significant step in the development of our defense strategy”, adding that his experience operating and deploying advanced air defence systems would give Adisyn insight into “both the operational requirements and commercial pathways in this sector”.

That last phrase is doing a lot of work. Defence markets are not won by good science alone. Procurement cycles can be long, validation requirements are exacting, and the end users are not generally impressed by investor-deck enthusiasm. Materials need to work in the real world, not merely under controlled laboratory conditions.

Adisyn knows this, judging by the way it has framed the Advisory Board. Its stated role is to help prioritise radar-related activities, translate technical capability into operationally relevant solutions, engage with commercial and government stakeholders, and open global defence networks.

That is the right shopping list. The market will now want evidence that it can be executed.

Market has already re-rated the story

The investor backdrop is lively. ASX data showed AI1 last at 21 cents, with a market capitalisation of about $223.6 million, following a sharp run in the stock during 2026. Market Index data shows AI1 closed at 21 cents on 1 May, up materially from 4.4 cents at the end of June 2025.

That sort of rerating means expectations are no longer modest. The company is being priced less like a managed IT services business and more like an emerging advanced materials play with semiconductor and defence optionality.

The appointment of Zimber strengthens the defence narrative, but it does not by itself validate the technology commercially. The next investor markers are likely to be further testing, real-world UAV integration, industrial manufacturing partnerships and signs of genuine customer engagement. Adisyn has put a decorated operator in the tent. Now it needs to show that the tent can become a factory, a supply chain and eventually a revenue stream.

BrainChip has added another distribution pathway for its Akida neuromorphic AI technology, signing a non-exclusive, worldwide IP distribution licence with South Korea’s ASICLAND. The deal allows ASICLAND to integrate BrainChip’s Akida IP into custom system-on-chip designs for multiple end customers, provided BrainChip signs off on the relevant licensing approvals.

For investors, the key point is that this is not a single-chip, single-customer arrangement. ASICLAND can use Akida across multiple customer engagements, including evaluation licences and multi-project wafer runs, which are commonly used to produce prototype and test silicon before anyone writes the bigger cheque for commercial deployment. If those customers proceed, the evaluation licences can be converted into production licences, with additional production licence fees payable to BrainChip.

That matters because BrainChip’s long-running challenge has not been invention. Akida has never lacked gee-whiz appeal. The market’s question has been simpler and more brutal: how does the IP turn into recurring revenue?

The model: upfront fees, royalties and optional services

The financial structure is the most investor-relevant part of the deal. BrainChip says the agreement includes upfront evaluation and production licence fees on a per-customer basis, ongoing volume-based royalties calculated on net sales of licensed products, and extra fees for optional services and software maintenance.

The company has not quantified the financial impact, but says it expects revenue to be material over time. That phrase will do some work. It gives investors a direction of travel, but not the speed limit, the distance or whether there are potholes. The valuation significance depends on how many ASICLAND customers move from prototype silicon to production, what end-markets they target, and whether volumes eventually justify meaningful royalty income.

Importantly, BrainChip retains ownership of its IP. ASICLAND is not permitted to sublicense it, meaning the Akida technology is incorporated only within ASICLAND-designed semiconductor products supplied to customers. That is a useful control point for BrainChip, because it keeps the company in the approval chain and preserves the potential to engage directly with end customers for extra support, services or commercial arrangements.

Why ASICLAND matters

ASICLAND is not just a reseller with a glossy brochure. The company is a Korea-based semiconductor design and turnkey services provider, described as a TSMC Value Chain Alliance partner with expertise across AI, memory, IoT/RF and automotive applications. It also has an R&D centre in Hsinchu, Taiwan, and business operations in San Jose in the United States.

That footprint is relevant because custom silicon adoption is rarely a straight line. Customers need design capability, foundry access, integration support and confidence that clever IP can survive the messy business of becoming working silicon. ASICLAND’s role is to help customers cross that bridge from architectural concept to functional chips.

BrainChip chief executive Sean Hehir said the partnership extends the company’s reach into a broader range of custom silicon programs, adding that ASICLAND’s SoC design capabilities and customer relationships make it “a strong partner for accelerating Akida adoption across multiple end markets, while maintaining the integrity of our IP and long-term royalty model.”

Market reaction and context

The deal landed with BRN already a heavily watched stock among Australian tech speculators. ASX company data showed BrainChip with a market capitalisation of about $352.75 million, while external market data showed the shares trading around 16.3 cents, up 0.8 cents or 4.84% during the session.

That pop is understandable. The agreement gives investors something they have long wanted to see: another potential commercial channel for Akida, tied to licence fees and royalties rather than one-off demonstrations. The ASX also listed the BrainChip-ASICLAND release at 9:01am on 4 May 2026, marking it as the company’s main price-sensitive news of the morning.

What investors should watch next

The deal is strategically tidy, but the real test is conversion. Evaluation licences are helpful. Prototype chips are better. Production licences are the prize. The difference between those stages is the difference between “interesting technology platform” and “revenue engine”.

The next markers to watch are customer names, the number of evaluation licences issued through ASICLAND, evidence of MPW prototype activity, conversion into production licences, and any disclosure of royalty-bearing products moving towards commercial manufacture.

For now, BrainChip has strengthened its route-to-market story in edge AI, industrial, automotive, consumer and IoT applications. The company still has to prove that partner ecosystem momentum can translate into material, repeatable revenue. But this deal gives Akida another seat at the silicon table - and for BrainChip shareholders, that is at least a more tangible prospect than another round of AI theme music.

Entropy Neurodynamics has produced the sort of early-stage biotech result that investors notice quickly, although they should still keep both feet planted on the lab floor.

The ASX-listed clinical-stage company reported that its Phase 2a study of TRP-8802, an oral psilocybin therapy used with structured psychotherapy, achieved a 75 percent response rate in treatment-resistant irritable bowel syndrome patients. The trial involved 12 patients who had previously failed multiple standard treatments, with clinical response defined as at least a 50-point reduction on the IBS Symptom Severity Score.

For context, Entropy says approved IBS therapies typically produce response rates of 17 percent to 44 percent, generally in less difficult non-refractory patient groups. That comparison is why the company is calling the result a breakthrough. In biotech parlance, that is a word best handled with tongs, but the signal is undeniably notable for a patient group with few reliable options.

The gut-brain angle

The important part for investors is not just the headline 75 percent number. The study also linked symptom improvement with changes in psychological insight and psychological flexibility, which supports Entropy’s thesis that IBS can be tackled through gut-brain axis modulation rather than simply dampening bowel symptoms.

Subtype results were also eye-catching. Patients with constipation-predominant IBS recorded a 100 percent response rate, albeit from only three patients. Mixed-type IBS delivered four responses from five patients, while diarrhoea-predominant IBS recorded two responses from four patients.

That is interesting rather than definitive. With only 12 patients, one patient can move the percentage dial substantially. Still, early-stage drug development is often about detecting whether there is enough biological smoke to justify looking for fire in a larger, controlled trial. On that measure, Entropy has given itself something to work with.

The safety sting in the tail

The safety readout was broadly described as consistent with expectations for psychedelic-assisted therapy, but it was not event-free. One serious adverse event, transient suicidal ideation, occurred and resolved with clinical support.

That matters. Psychedelic therapy is not a simple pill-in-a-box model. Screening, supervision, integration and clinical infrastructure are central to the treatment approach. For investors, that creates both a barrier to entry and a commercial constraint. A therapy that needs trained clinicians and structured psychotherapy may command premium pricing, but it also carries execution complexity.

TRP-8803 is the real commercial target

While the trial used TRP-8802, the bigger commercial story is TRP-8803, Entropy’s proprietary IV-infused psilocin formulation. The company says the oral psilocybin program was designed to de-risk the indication and mechanism for TRP-8803.

The logic is straightforward. Oral psilocybin can be variable because of metabolism and timing. Entropy argues that IV psilocin could offer faster onset, better control over dose, depth and duration of effect, and a more scalable treatment model. If that proves true, TRP-8803 could be the product with the cleaner clinical and commercial package.

Chief executive Jason Carroll said the data represented “a breakthrough moment for Entropy and for the treatment of IBS”, adding that the 75 percent response rate in a treatment-resistant population was “clinically unprecedented”. He also said the dataset was “mechanistically coherent”, with clinical outcomes aligning with improvements in psychological drivers.

The market carrot is large

Entropy is pointing to a substantial addressable market. The company says IBS affects about 10.4 million patients in the US, where annual spending exceeds US$60 billion, and more than one million patients in Australia. It also says treatment-resistant IBS patients commonly cycle through multiple therapies and can incur meaningful out-of-pocket costs.

That gives the story a familiar biotech shape: a large market, inadequate current options, promising early data and a proprietary next-generation asset. The company also flagged potential partnering discussions, larger trials, grant funding opportunities and a US-focused development path.

The obvious catch is that a 12-patient open-label study is not the same as a randomised, placebo-controlled pivotal trial. Open-label designs are useful for early mechanistic work, but they leave plenty of room for placebo effects, selection bias and over-interpretation. IBS trials can also be noisy, given fluctuating symptoms and the influence of psychological and behavioural factors.

Investor takeaway

For retail investors, Entropy’s result is best viewed as a value-inflection data point, not a finish line. The company has generated a strong early efficacy signal in a difficult indication, with a plausible mechanistic story and a more commercially targeted follow-on asset in TRP-8803.

The next questions are more prosaic but more important: can the response be replicated in a larger controlled trial, can safety be managed at scale, can regulators be satisfied, and can the treatment model work commercially outside specialist centres?

Biotech investors are used to castles being built on mouse studies and mist. This one at least has human data. Now Entropy has to show that the 75 percent signal is not just impressive, but repeatable.

Sprintex has signed an exclusive distribution agreement with Washnah Trading Co. LLC for Saudi Arabia, giving the small-cap clean air technology group a formal channel into one of the world’s most infrastructure-hungry markets.

The agreement covers Sprintex’s G-Series, GA and GR high-speed Jet Blowers across the Kingdom. For investors, the headline number is not immediately huge, but it is tangible: once regulatory approvals are secured, Washnah must deliver minimum secured orders of US$500,000, or about A$701,000, for each 12-month period. Excess orders can be carried forward, which gives the arrangement some flexibility if demand arrives in lumps rather than neat annual parcels.

The initial term runs to 31 March 2029, with a two-year extension available if milestones are met. These milestones include vendor registration with Saudi Arabia’s National Water Company and product approvals via the SABER platform, part of the Saudi Standards, Metrology and Quality Organisation system.

That sounds like regulatory plumbing, and it is. But for industrial equipment suppliers, particularly those selling into government-linked water and wastewater projects, being on the approved vendor list is often the difference between watching the feast and getting a seat at the table.

Airport tender could be the company maker

The sizzle is Washnah’s tender for wastewater treatment works at King Salman International Airport, where Sprintex’s high-speed turbo blowers have been specified exclusively.

The tender includes about 30 Sprintex units ranging from 11 kW to 675 kW, covering process stages such as grease and grit removal, aeration tanks, membrane bioreactor tanks, sludge holding tanks and equalisation tanks. The package also includes acoustic enclosures, control panels with variable frequency drives and program logic controllers, IoT monitoring and commissioning support from Sprintex engineers.

Sprintex puts the potential opportunity at more than A$5 million, based on supply of blower content only. Tender award is expected in the second half of calendar 2026.

For context, Sprintex is a company with a market value of about A$52 million on ASX data and its shares were recently around 7.4 cents, according to market data. That means a single A$5 million equipment opportunity is not pocket change for the company, even allowing for the obvious caveat that a tender is not a purchase order.

Why the airport matters

King Salman International Airport is no ordinary terminal upgrade with new carpet and a brighter duty-free section. The project, based in Riyadh and owned by Saudi Arabia’s Public Investment Fund, is expected to cover 57 square kilometres and include six parallel runways. The airport is targeting capacity of up to 100 million passengers by 2030 and 185 million by 2050.

The official airport site says the development will include six runways, six terminals, a royal terminal, private aviation facilities, a cargo and logistics hub and real estate areas. It is designed as a core plank in Saudi Arabia’s push to turn Riyadh into a global hub for business, tourism and logistics.

For Sprintex, the attractive part is less glamorous than the architecture but arguably more dependable: wastewater treatment. Airports, cities, desalination plants and industrial facilities need continuous-duty systems. In these applications, energy efficiency is not green window dressing - it goes straight to operating costs.

Management talks scale and validation

Sprintex managing director and chief executive Jay Upton described the Saudi agreement and airport tender as “a significant milestone” in the company’s international expansion.

“The scale of the tender - approximately 30 high-power turbo blowers up to 675 kW across the full wastewater treatment works - provides powerful early validation of both our technology platform and the strength of the partnership,” Upton said.

He added that Saudi Vision 2030’s infrastructure programme creates a long-term opportunity for Sprintex’s energy-efficient blower solutions.

That is the nub of the investment case. Sprintex has been repositioning from its better-known automotive supercharger heritage toward industrial clean air applications, including wastewater, aquaculture, paper milling, pharmaceuticals and clean energy compressors. The Saudi deal gives it a local partner, a defined market and a flagship project to chase.

What investors should watch next

The next milestones are clear enough: Saudi regulatory approvals, National Water Company vendor registration, conversion of the airport tender into an awarded contract and evidence that Washnah can build a recurring pipeline beyond the glamour project.

The risk is equally clear. The A$5 million tender remains contingent, and large infrastructure projects can move with all the speed of a camel in a sandstorm when procurement, approvals and government priorities are involved. Minimum annual orders only kick in after approvals, so investors should be careful not to bank the revenue before the paperwork lands.

Still, for a sub-A$100 million ASX industrial technology stock, this is a credible door-opener. Sprintex now has exclusivity in Saudi Arabia, a local partner with wastewater sector relationships, minimum order commitments and a tender tied to one of the Middle East’s highest-profile infrastructure builds.

The runway is long, but at least Sprintex has found a gate.

Swift TV Ltd has given small-cap investors something more tangible than the usual tech-sector promise jar: installed hardware, contracted sites and a near-term deployment timetable. The company says 2,758 Swift TV screens have been installed across seven customer sites in just seven weeks, spanning resources and aged care customers, including global oil and gas operators and leading aged care providers. A further eight sites are scheduled for completion by 1 June 2026.

That matters because Swift has been trying to shift the investor conversation from “product development” to “commercial rollout”. In microcap tech, that transition is often where the wheels either start turning or fall off entirely. Swift is now arguing the former.

Recurring revenue is the prize

The key phrase for investors is recurring subscription revenue. Swift says revenue commences or expands as each site is commissioned, with deployments typically supported by multi-year contracts. That is a more attractive model than lumpy hardware sales, assuming the company can keep installation costs, support costs and churn under control.

The company does not provide contract values, average revenue per screen, gross margins or payback periods, so investors are still being asked to fill in a fair few blanks. But the operational metric is worth watching: 2,758 screens in seven weeks suggests the rollout process is no longer a lab exercise.

Chief executive Brian Mangano put it plainly, saying: “The speed of deployment we are seeing is a strong validation of the Swift TV platform and marks a clear transition from product development to commercial rollout.” He added that installing more than 2,700 screens in seven weeks showed the company’s ability to scale across multiple sites and that Swift is focused on converting deployments into recurring subscription revenue.

The 5,000-unit order is a confidence signal - with a caveat

Swift has also ordered another 5,000 units from a Google certified supplier to support its near-term pipeline. On one hand, that is a useful sign that management sees enough contracted or prospective demand to warrant inventory build-up. On the other hand, investors should watch the balance sheet implications.

Hardware orders cost money before revenue arrives. The company has not disclosed the unit cost, payment terms or whether customer contracts carry upfront contributions. For a company of Swift’s size, execution is not just about selling screens - it is about funding the rollout without squeezing working capital too hard.

At the time of writing, ASX data showed Swift shares at $0.009, with a market capitalisation of about $11.25 million. That valuation leaves little room for heroic assumptions, but it also means any credible growth in contracted recurring revenue could become material.

Why mining camps and aged care make sense

Swift’s chosen sectors are not random. Mining, oil and gas, aged care and hospitality all involve residents, workers or guests spending extended time in managed accommodation. That creates a natural use case for in-room entertainment, communications, messaging and engagement tools.

For resources customers, the attraction is likely to be workforce engagement and site communications, especially in remote camps where amenity can help with retention. For aged care operators, the platform may help with resident entertainment, family engagement and facility communications. Swift describes its product as an all-in-one connected TV platform designed to unify entertainment, communication and engagement, with integrations aimed at improving business outcomes.

The strategic logic is tidy enough. The investor question is whether Swift can turn that logic into scalable margins.

The next milestones

There are three things investors should watch from here. First, whether the eight additional sites due by 1 June are completed on schedule. Second, whether Swift starts providing harder revenue metrics, such as annualised recurring revenue, revenue per screen, contract length and gross margin. Third, whether the 5,000-unit order translates into commissioned sites rather than sitting in inventory like a very modern-looking Christmas tree pile.

Swift has not yet given the market the full economics of the rollout. But it has provided a clearer operational scoreboard. Screens are being installed, customers are being commissioned and the company says recurring revenue is now beginning to flow or expand as sites go live.

For a sub-$15 million ASX technology company, that is a meaningful step. The next job is to prove that scale can come with cash flow, not just more screens on walls.